Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 7/2014

01-07-2014 | Original paper

Associations between circulating 1,25(OH)2D concentration and odds of metachronous colorectal adenoma

Authors: Elizabeth A. Hibler, Christine L. Sardo Molmenti, Peter Lance, Peter W. Jurutka, Elizabeth T. Jacobs

Published in: Cancer Causes & Control | Issue 7/2014

Login to get access

Abstract

Cellular-level studies demonstrate that the availability of the secosteroid hormone 1α,25-dihydroxyvitamin D [1,25(OH)2D] to colon cells promotes anti-carcinogenic activities. Although epidemiological data are relatively sparse, suggestive inverse trends have been reported between circulating 1,25(OH)2D concentration and colorectal neoplasia. We therefore sought to evaluate the relationship between circulating 1,25(OH)2D concentrations and odds for metachronous colorectal adenomas among 1,151 participants from a randomized trial of ursodeoxycholic acid for colorectal adenoma prevention. No relationship between 1,25(OH)2D and overall odds for metachronous lesions was observed, with ORs (95 % CIs) of 0.80 (0.60–1.07) and 0.81 (0.60–1.10) for participants in the second and third tertiles, respectively, compared with those in the lowest (p-trend = 0.17). However, a statistically significant inverse association was observed between circulating 1,25(OH)2D concentration and odds of proximal metachronous adenoma, with an OR (95 % CI) of 0.71 (0.52–0.98) for individuals in the highest tertile of 1,25(OH)2D compared with those in the lowest (p-trend = 0.04). While there was no relationship overall between 1,25(OH)2D and metachronous distal lesions, there was a significantly reduced odds for women, but not men, in the highest 1,25(OH)2D tertile compared with the lowest (OR 0.53; 95 % CI 0.27–1.03; p-trend = 0.05; p-interaction = 0.08). The observed differences in associations with proximal and distal adenomas could indicate that delivery and activity of vitamin D metabolites in different anatomic sites in the colorectum varies, particularly by gender. These results identify novel associations between 1,25(OH)2D and metachronous proximal and distal colorectal adenoma, and suggest that future studies are needed to ascertain potential mechanistic differences in 1,25(OH)2D action in the colorectum.
Literature
1.
Haussler MR, Haussler CA, Bartik L et al (2008) Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr Rev 66:S98–S112PubMedCrossRef
2.
Jafri NS, Gould M, El-Serag HB, Duan Z, Davila JA (2013) Incidence and survival of colorectal cancer among Hispanics in the United States: a population-based study. Dig Dis Sci 58:2052–2060PubMedCrossRef
3.
Gawron AJ, Yadlapati R (2013) Disparities in endoscopy use for colorectal cancer screening in the United States. Dig Dis Sci 59(3):530–537
4.
Laiyemo AO, Doubeni C, Sanderson AK 2nd et al (2011) Likelihood of missed and recurrent adenomas in the proximal versus the distal colon. Gastrointest Endosc 74:253–261PubMedCentralPubMedCrossRef
5.
Gandini S, Boniol M, Haukka J et al (2011) Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 128:1414–1424PubMedCrossRef
6.
Lee JE, Li H, Chan AT et al (2011) Circulating levels of vitamin D and colon and rectal cancer: the Physicians’ Health Study and a meta-analysis of prospective studies. Cancer Prev Res (Phila) 4:735–743CrossRef
7.
Touvier M, Chan DS, Lau R et al (2011) Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 20:1003–1016PubMedCrossRef
8.
Jacobs ET, Alberts DS, Benuzillo J, Hollis BW, Thompson PA, Martinez ME (2007) Serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence. J Steroid Biochem Mol Biol 103:752–756PubMedCentralPubMedCrossRef
9.
Slattery ML, Neuhausen SL, Hoffman M et al (2004) Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. Int J Cancer 111:750–756PubMedCrossRef
10.
Wei MY, Garland CF, Gorham ED, Mohr SB, Giovannucci E (2008) Vitamin D and prevention of colorectal adenoma: a meta-analysis. Cancer Epidemiol Biomarkers Prev 17:2958–2969PubMedCrossRef
11.
Zheng XE, Lipka S, Li T et al (2013) The relationship of vitamin D status, smoking, and colorectal adenoma: a retrospective study in an ethnically diverse community. J Steroid Biochem Mol Biol 136:280–283PubMedCrossRef
12.
Bouillon R, Lieben L, Mathieu C, Verstuyf A, Carmeliet G (2013) Vitamin D action: lessons from VDR and Cyp27b1 null mice. Pediatr Endocrinol Rev 10(Suppl 2):354–366PubMed
13.
Ryan JW, Anderson PH, Turner AG, Morris HA (2013) Vitamin D activities and metabolic bone disease. Clin Chim Acta 425C:148–152CrossRef
14.
Skinner HG, Schwartz GG (2008) Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 17:2302–2305PubMedCentralPubMedCrossRef
15.
Jacobs E, Martinez ME, Buckmeier J, Lance P, May M, Jurutka P (2011) Circulating fibroblast growth factor-23 is associated with increased risk for metachronous colorectal adenoma. J Carcinog 10:3PubMedCentralPubMedCrossRef
16.
Feskanich D, Ma J, Fuchs CS et al (2004) Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 13:1502–1508PubMed
17.
Platz EA, Hankinson SE, Hollis BW et al (2000) Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum. Cancer Epidemiol Biomarkers Prev 9:1059–1065PubMed
18.
Alberts DS, Martinez ME, Hess LM et al (2005) Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 97:846–853PubMedCrossRef
19.
Ritenbaugh C, Aickin M, Taren D et al (1997) Use of a food frequency questionnaire to screen for dietary eligibility in a randomized cancer prevention phase III trial. Cancer Epidemiol Biomarkers Prev 6:347–354PubMed
20.
Egan JB, Thompson PA, Ashbeck EL et al (2010) Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence. Cancer Res 70:1496–1504PubMedCentralPubMedCrossRef
21.
Hollis BW (2007) Assessment of circulating 25(OH)D and 1,25(OH)2D: emergence as clinically important diagnostic tools. Nutr Rev 65:S87–S90PubMedCrossRef
22.
Jacobs ET, Alberts DS, Foote JA et al (2008) Vitamin D insufficiency in southern Arizona. Am J Clin Nutr 87:608–613PubMed
23.
Mickey RM, Greenland S (1989) The impact of confounder selection criteria on effect estimation. Am J Epidemiol 129:125–137PubMed
24.
Hong SN, Kim JH, Choe WH et al (2012) Circulating vitamin D and colorectal adenoma in asymptomatic average-risk individuals who underwent first screening colonoscopy: a case–control study. Dig Dis Sci 57:753–763PubMedCrossRef
25.
Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H (2011) Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 29:3775–3782PubMedCrossRef
26.
Jacobs ET, Hibler EA, Lance P, Sardo CL, Jurutka PW (2013) Association between circulating concentrations of 25(OH)D and colorectal adenoma: a pooled analysis. Int J Cancer 133:2980–2988PubMed
27.
Thompson PA, Wertheim BC, Roe DJ et al (2009) Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. Cancer Prev Res (Phila) 2:1023–1030CrossRef
28.
Thompson PA, Wertheim BC, Roe DJ et al (2009) Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. Cancer Prev Res (Phila Pa) 2:1023–1030CrossRef
29.
Moan J, Lagunova Z, Lindberg FA, Porojnicu AC (2009) Seasonal variation of 1,25-dihydroxyvitamin D and its association with body mass index and age. J Steroid Biochem Mol Biol 113:217–221PubMedCrossRef
30.
31.
Liu S, Gupta A, Quarles LD (2007) Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 16:329–335PubMedCrossRef
32.
Marsell R, Jonsson KB (2010) The phosphate regulating hormone fibroblast growth factor-23. Acta Physiol (Oxf) 200:97–106CrossRef
33.
Marsell R, Mirza MA, Mallmin H et al (2009) Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int 20:1167–1173PubMedCrossRef
34.
35.
36.
Jacobs ET, Thompson PA, Martinez ME (2007) Diet, gender, and colorectal neoplasia. J Clin Gastroenterol 41:731–746PubMedCrossRef
37.
Bufill JA (1990) Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 113:779–788PubMedCrossRef
38.
Albuquerque C, Baltazar C, Filipe B et al (2010) Colorectal cancers show distinct mutation spectra in members of the canonical WNT signaling pathway according to their anatomical location and type of genetic instability. Genes Chromosom Cancer 49:746–759PubMedCrossRef
39.
Gervaz P, Bucher P, Morel P (2004) Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol 88:261–266PubMedCrossRef
40.
Koestler DC, Li J, Baron JA et al (2013) Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon. Mod Pathol 27(1):145–155
41.
Slatter ML, Yakumo K, Hoffman M, Neuhausen S (2001) Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control 12:359–364PubMedCrossRef
42.
Slattery ML, Wolff RK, Curtin K et al (2009) Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. Mutat Res 660:12–21PubMedCentralPubMedCrossRef
43.
de Jonge V, Sint Nicolaas J, van Leerdam ME, Kuipers EJ, Veldhuyzen van Zanten SJ (2011) Systematic literature review and pooled analyses of risk factors for finding adenomas at surveillance colonoscopy. Endoscopy 43:560–572PubMedCrossRef
44.
Gao QY, Chen HM, Sheng JQ et al (2010) The first year follow-up after colorectal adenoma polypectomy is important: a multiple-center study in symptomatic hospital-based individuals in China. Front Med China 4:436–442PubMedCrossRef
45.
Caldarella A, Crocetti E, Messerini L, Paci E (2013) Trends in colorectal incidence by anatomic subsite from 1985 to 2005: a population-based study. Int J Colorectal Dis 28:637–641PubMedCrossRef
46.
Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB (2011) Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. Int J Cancer 128:1668–1675PubMedCentralPubMedCrossRef
47.
Ding EL, Mehta S, Fawzi WW, Giovannucci EL (2008) Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women’s Health Initiative randomized trial. Int J Cancer 122:1690–1694PubMedCrossRef
48.
Protiva P, Cross HS, Hopkins ME et al (2009) Chemoprevention of colorectal neoplasia by estrogen: potential role of vitamin D activity. Cancer Prev Res (Phila) 2:43–51CrossRef
49.
Papaxoinis K, Triantafyllou K, Sasco AJ, Nicolopoulou-Stamati P, Ladas SD (2010) Subsite-specific differences of estrogen receptor beta expression in the normal colonic epithelium: implications for carcinogenesis and colorectal cancer epidemiology. Eur J Gastroenterol Hepatol 22:614–619PubMedCrossRef
50.
Egan JB, Thompson PA, Vitanov MV et al (2010) Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate beta-catenin activity in colon cancer cells. Mol Carcinog 49:337–352PubMedCentralPubMed
51.
Palmer HG, Gonzalez-Sancho JM, Espada J et al (2001) Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154:369–387PubMedCentralPubMedCrossRef
52.
Norman AW (2008) From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 88:491S–499SPubMedCrossRef
53.
Jacobs ET, Van Pelt C, Forster RE et al (2013) CYP24A1 and CYP27B1 polymorphisms modulate vitamin D metabolism in colon cancer cells. Cancer Res 73:2563–2573PubMedCentralPubMedCrossRef
54.
Abbas S, Linseisen J, Slanger T et al (2008) The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomarkers Prev 17:1339–1343PubMedCrossRef
55.
Lauridsen AL, Vestergaard P, Hermann AP et al (2005) Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of Gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif Tissue Int 77:15–22PubMedCrossRef
56.
Hibler EA, Jacobs ET, Dampf Stone A, Sardo CL, Galligan MA, Jurutka PW (2014) Associations between vitamin D binding protein isotypes, circulating 25(OH)D levels, and vitamin D metabolite uptake in colon cancer cells. Cancer Prev Res (Phila) 7(4):426–434
57.
Hibler EA, Hu C, Jurutka PW, Martinez ME, Jacobs ET (2012) Polymorphic variation in the GC and CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 21:368–375PubMedCentralPubMedCrossRef
58.
Jacobs ET, Scragg R (2008) Vitamin D and health. Complet Nutr 3:7–9
59.
Lagunova Z, Porojnicu AC, Lindberg F, Hexeberg S, Moan J (2009) The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res 29:3713–3720PubMed
60.
Metadata
Title
Associations between circulating 1,25(OH)2D concentration and odds of metachronous colorectal adenoma
Authors
Elizabeth A. Hibler
Christine L. Sardo Molmenti
Peter Lance
Peter W. Jurutka
Elizabeth T. Jacobs
Publication date
01-07-2014
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 7/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-014-0382-6

Other articles of this Issue 7/2014

Cancer Causes & Control 7/2014 Go to the issue

Original paper

Dairy food and nutrient intake in different life periods in relation to risk of ovarian cancer

Original paper

Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses’ Health Study II

Original Paper

First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants

Original paper

Insulin-like growth factor-1, growth hormone, and daily cycling estrogen are associated with mammographic density in premenopausal women

Review

What causes breast cancer? A systematic review of causal attributions among breast cancer survivors and how these compare to expert-endorsed risk factors

Original paper

Gene–environment interactions between JAZF1 and occupational and household lead exposure in prostate cancer among African American men
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits